Latest news with #AmroAlbanna
Business Wire
07-07-2025
- Business
- Business Wire
Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced its bitXbio (pronounced 'bit by bio') Plan, a next-generation capitalization and monetization public-market strategy integrating Bitcoin (BTC) in support of its biotech commercialization efforts. The initiative will be anchored by a Bitcoin-backed treasury strategy that was recently approved by its board of directors, aimed at expanding Aditxt's capital ecosystem and aligning its enterprise value (EV) with projected monetization opportunities starting in 2026. Aditxt is a social innovation platform that currently operates two programs focused on autoimmunity and early disease and cancer detection. The Company seeks to grow by A cquiring, B uilding, and C apitalizing high-growth ventures across health and biotechnology. The bitXbio Plan marks a deliberate move to broaden the company's capital accessibility and align its current market value with its commercialization roadmap — blending Bitcoin-backed reserve with capital access to support scale and liquidity. 'bitXbio™ is a forward-looking strategy designed to align our capital structure with the value-creation potential of our biotech pipeline,' said Amro Albanna, Co-founder and CEO of Aditxt. 'As we look to strengthen our balance sheet and enterprise value, we plan to seek to integrate digital currency reserves, subject to the availability of funds, and continue to utilize our equity line to support the commercialization of high-impact innovations. We believe that this approach positions us to unlock shareholder value as we strive to execute on planned monetization milestones, starting in 2026.' Plan Highlights Bitcoin-Backed Treasury Strategy Aditxt plans to establish a Bitcoin reserve, subject to the availability of funds, to align its market value in support of its commercialization activities, and to unlock a new class of opportunities with digital asset economies. Equity Line Facility Aditxt intends to strategically deploy capital drawn on its existing equity line facility to meet its existing financial obligations and in support of its commercialization roadmap and upcoming monetization events. Aditxt has approximately $125 million in availability under its common stock purchase agreement with its equity line investor, of which it presently has the ability to sell up to 50 million shares of its common stock pursuant to its registration statement on Form S-1, which was declared effective by the SEC on June 30, 2025. Planned Capitalization Events in 2026 As part of its 2026 monetization strategy, Aditxt is positioning Pearsanta for an initial public offering. The plan reflects Aditxt's broader vision to build a global, socially driven biotech platform, capable of commercializing and monetizing innovation through digital capitalization. About Aditxt, Inc. Aditxt, Inc. is a social innovation platform accelerating promising health innovations. Aditxt's ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt's strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder's voice is heard and valued, and empowers collective progress. The Company currently operates two programs focused on immune health and precision health. Through the proposed acquisition of Evofem under the July 2024 Amended and Restated Merger Agreement between Evofem, Aditxt and Adifem, Inc., as amended (the "A&R Merger Agreement"), Aditxt aims to introduce an additional program dedicated to women's health. The companies are working toward a targeted close in the second half of 2025. The closing of the transaction with Evofem is subject to several conditions, including but not limited to approval of the transaction by Evofem's shareholders and Aditxt raising sufficient capital to fund its obligations at closing. These obligations include cash payments of approximately $17 million for Evofem, which includes approximately $15.2 million required to satisfy Evofem's senior secured noteholder; should Aditxt fail to secure these funds, Evofem's senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that the transaction will ultimately close. Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "achieving," "advancing," "aim," "are working to," "believe," "completing," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to anticipated availability of funds to pursue the purchase of digital assets; expected growth of Aditxt; Aditxt's ability to successfully execute its mission to accelerate and monetize promising health innovations, and magnitude thereof; Aditxt's ability to complete the proposed initial public offering of Pearsanta on the proposed timeline, if at all; and Aditxt's ability to close the planned acquisition of Evofem, including to meet all closing conditions, and the timing thereof. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in each company's SEC filings, including Aditxt's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 21, 2025, and any subsequent Form 10-Q filings. All forward-looking statements are expressly qualified in their entirety by such factors. Aditxt undertakes no duty to update any forward-looking statement except as required by law. For more information, please visit bitXbio™ is a trademark of Aditxt, Inc. All rights reserved. Follow Aditxt on:
Business Wire
26-06-2025
- Business
- Business Wire
Aditxt to Present at Wall Street Reporter's NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, is pleased to announce that Co-founder and CEO Amro Albanna will be presenting at Wall Street Reporter's NEXT SUPER STOCK livestream event on June 26, 2025 at 1:00 p.m. ET. Mr. Albanna will discuss Aditxt's innovation acceleration business model, overview and status of Aditxt's two programs with focus on autoimmunity and early cancer detection, and status of the pending acquisition of Evofem Biosciences, Inc. The livestream will start at 1:00 p.m. ET and will be followed by a question-and-answer session. To learn more about the event, and join, please click: ABOUT: Wall Street Reporter NEXT SUPER STOCK livestream Wall Street Reporter (Est. 1843) is the leading financial news provider, focused on giving investors direct access to CEOs of promising, publicly-traded companies, and market experts. Next Super Stock conference: Wall Street Reporter's NEXT SUPER STOCK Live! conference is dedicated to featuring select companies that have near-term catalysts in place which can drive transformational growth (and stock appreciation) in the months ahead. Click here to join the next livestream event: About Aditxt, Inc. Aditxt, Inc. is a social innovation platform accelerating promising health innovations. Aditxt's ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt's strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder's voice is heard and valued, and empowers collective progress. The Company currently operates two programs focused on immune health, and precision health. Through the proposed acquisition of Evofem under the July 2024 Amended and Restated Merger Agreement between Evofem, Aditxt and Adifem, Inc., as amended (the "A&R Merger Agreement"), Aditxt aims to introduce an additional program dedicated to women's health. The companies are working toward a targeted close in the second half of 2025. The closing of the transaction with Evofem is subject to several conditions, including but not limited to approval of the transaction by Evofem's shareholders and Aditxt raising sufficient capital to fund its obligations at closing. These obligations include cash payments of approximately $17 million for Evofem, which includes approximately $15.0 million required to satisfy Evofem's senior secured noteholder; should Aditxt fail to secure these funds, Evofem's senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem. No assurance can be provided that all of the conditions to closing will be obtained or satisfied, or that the transaction will ultimately close. For more information, please visit Follow Aditxt on:
Business Wire
19-05-2025
- Business
- Business Wire
Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ('Aditxt' or the 'Company'), a social innovation platform accelerating promising health innovations, today announced that it has determined it is in the best interest of the Company and its stockholders to terminate the previously announced Arrangement Agreement with Appili Therapeutics, Inc. The Arrangement Agreement, originally announced in April 2024, had been amended several times to extend key milestones and accommodate changing circumstances. Despite these efforts, Aditxt has concluded that it is no longer strategically aligned to move forward under the terms of the agreement. Management intends to formally notify Appili of the termination, effective May 31, 2025. 'We greatly appreciate the Appili team and respect the important work they are doing,' said Amro Albanna, Co-Founder and CEO of Aditxt. 'After careful consideration, we've determined that this would be the best course of action.' Further details will be provided as appropriate. About Aditxt, Inc. Aditxt, Inc. ® is a social innovation platform accelerating promising health innovations. Aditxt's ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt's strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder's voice is heard and valued, and empowers collective progress. Aditxt currently operates two programs focused on immune health and precision health. The Company plans to introduce an additional program dedicated to women's health. To this end, Aditxt has entered into a Merger Agreement with Evofem Biosciences, Inc. ('Evofem') (OTCQB: EVFM). The program will be designed to function autonomously while collectively advancing Aditxt's mission of discovering, developing, and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of the transaction with Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. These obligations include cash payments of approximately $17 million for Evofem, which includes approximately $15.2 million required to satisfy Evofem's senior secured noteholder; should Aditxt fail to secure these funds, Evofem's senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that the transaction will ultimately close. For more information, . Follow us on: LinkedIn: Facebook: Forward-Looking Statements Certain statements in this press release constitute 'forward-looking statements' within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company's ongoing and planned product and business development; the Company's ability to finance and execute its strategic M&A initiatives; the Company's ability to obtain the necessary funding and partner to commence clinical trials; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth, and strategies; the Company's ability to raise additional capital; expected usage of the Company's ELOC and ATM facilities; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled 'Risk Factors' in Aditxt's most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Associated Press
09-04-2025
- Business
- Associated Press
Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements
Aditxt, Inc. (NASDAQ: ADTX) ('Aditxt' or the 'Company'), a social innovation platform dedicated to accelerating promising health innovations, announced today that it received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC ('Nasdaq') that the Company has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). The hearing before the Hearings Panel scheduled to take place on April 22, 2025, has been cancelled. The Company's common stock will continue to trade on the Nasdaq Capital Market under the symbol ADTX. 'We are pleased to have regained compliance with Nasdaq's listing requirements. We continue to remain focused on advancing our progress towards addressing autoimmunity, cancer, and other pressing health challenges,' said Amro Albanna, Co-founder and CEO of Aditxt. About Aditxt Aditxt, Inc.® is a social innovation platform dedicated to accelerating promising health innovations. Aditxt's ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to 'Make Promising Innovations Possible Together.' The innovation platform is the cornerstone of Aditxt's strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that socializes innovation, ensures every stakeholder's voice is heard and valued, and empowers collective progress. For more information, Forward-Looking Statements Certain statements in this press release constitute 'forward-looking statements' within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company's ongoing and planned product and business development; the Company's ability to finance and execute its strategic M&A initiatives; the Company's ability to obtain the necessary funding and partner to commence clinical trials; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth, and strategies; the Company's ability to raise additional capital; expected usage of the Company's ELOC and ATM facilities; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled 'Risk Factors' in Aditxt's most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. SOURCE: Aditxt, Inc. Copyright Business Wire 2025. PUB: 04/09/2025 08:15 AM/DISC: 04/09/2025 08:15 AM
Associated Press
02-04-2025
- Business
- Associated Press
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
Event exploring the escalating threat of emerging infectious diseases Discussion covering going-private transaction with Aditxt, strategic growth partner HALIFAX, Nova Scotia, April 02, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the 'Company' or 'Appili'), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that its President and CEO, Don Cilla, Pharm.D., M.B.A., will join Aditxt, Inc. (NASDAQ: ADTX) ('Aditxt') Co-founder and CEO, Amro Albanna, for the Aditxt Weekly Update on April 4, 2025. The discussion will cover the Company's recent operational highlights, including $117 million in new federal funding applications, and the status of the going-private transaction with Aditxt. Dr. Cilla will join Aditxt to explore the escalating threat of emerging infectious diseases and highlight the vital role of strategic partnerships in developing innovative treatments and improving global public health. The Aditxt Weekly Update will also provide insights into Appili's diverse near-to-market portfolio, designed to address critical unmet patient needs. Additionally, the discussion will highlight Appili's proven track record in securing non-dilutive funding, showcasing $33.2 million in prior government awards and the recent submission of $117 million in new federal funding applications. By leveraging financial support, Appili can strengthen its ability to accelerate the development of new and existing infectious disease treatments aligned with public health priorities. Participants are encouraged to register in advance by clicking here. The event will also include a Q&A session, with questions welcomed at [email protected]. Appili will join additional Aditxt Weekly Updates throughout the year. About Appili Therapeutics Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili's goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit Forward Looking Statements This news release contains 'forward-looking statements', including with respect to the potential for partnered projects to be developed, the potential that Appili will receive government awards and / or contracts related to its proposal submissions, the availability of future funding under the USAFA cooperative agreement, the Company's development plan with respect to ATI-1701 and the expected timing and process to complete the Transaction. Wherever possible, words such as 'may,' 'would,' 'could,' 'should,' 'will,' 'anticipate,' 'believe,' 'plan,' 'expect,' 'intend,' 'estimate,' 'potential for' and similar expressions have been used to identify these forward-looking statements. These forward-looking statements reflect the current expectations of the Company's management for future growth, results of operations, performance and business prospects and opportunities and involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, those listed in (i) the annual information form of the Company dated June 25, 2024, (ii) the Circular, and (iii) and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law. Don Cilla, Pharm.D. M.B.A.
